Is there anyone holding AKT? Let's talk about its role and future development analysis #美国稳定币法案

1. Cryptocurrency Field #加密市场回调

Token AKT: Used for payment of decentralized cloud computing resources, current price $1.626 (May 2025), 24-hour increase of 7.56%, circulating market value $2.596 billion.

Potential and Risks:

Positive Factors: Technological innovation (distributed cloud platform), increased institutional investment, recovery of market sentiment.

Risks: High volatility of cryptocurrencies, regulatory uncertainty, and competitive pressure (e.g., centralized platforms like AWS)

4H highest ¥11.317 24H volume 5,199,100

24H lowest ¥10.234 24H amount ¥58,557,900

24H volatility +10.58% Volume ratio 0.98

Total market value ¥2.591 billion BTC correlation 0.73

Historical highest ¥58.679 Historical lowest ¥1.205

2. The Origin and Biological Role of AKT

AKT (Protein Kinase B, PKB) is a core node of the PI3K/AKT/mTOR signaling pathway, belonging to the serine/threonine kinase family, including three subtypes (AKT1, AKT2, AKT3), playing a key role in cell growth, proliferation, metabolism, and apoptosis regulation.

Physiological Functions:

Cell Survival: Promotes cell survival by inhibiting pro-apoptotic proteins (e.g., Bad, FoxO).

Metabolic Regulation: AKT2 is involved in the insulin signaling pathway, regulating glucose uptake; AKT1/3 more significantly affects tumor occurrence.

Cancer-related: Overactivation of AKT (e.g., PTEN loss, AKT mutations) is closely related to the occurrence, metastasis, and drug resistance of various tumors (breast cancer, prostate cancer, ovarian cancer, etc.).

Pathological Mechanism:

Abnormal AKT signaling is associated with diseases such as diabetes, neurodegenerative diseases, and leukemia. In leukemia, sustained activation of AKT can promote malignant cell proliferation and inhibit apoptosis, which is related to treatment resistance.

3. The Research and Development Progress and Trends of AKT

Combination Therapy: AKT inhibitors combined with endocrine therapy, chemotherapy, or immunotherapy have become mainstream directions, such as the phase III trial of Capivasertib combined with paclitaxel for treating triple-negative breast cancer.

Indication Expansion: From prostate cancer to endometrial cancer and other cancer types, covering a wide patient population with abnormal activation of the PI3K/AKT pathway. #美国稳定币法案

Safety Optimization: Reduces side effects through subtype-selective inhibition (e.g., targeting only AKT1 mutants), enhancing the therapeutic window. #欧盟隐私币禁令 $BTC$SOL$ETH